OBI filed the application of Phase III human clinical study for the active cancer immunotherapy OBI-822, Adagloxad Simolenin, to the drug administrations of Mexico

1. Date of occurrence of the event: Mar 12, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office 4. Reciprocal shareholding ratios: No applicable 5. Cause of occurrence: OBI filed the application of Phase III human clinical study for the active cancer immunotherapy OBI-822, […]